Suchergebnisse - "Strickler, John H"

PubPharm (121)

31

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Jia, J. | Howard, L. | Liu, Y. | +5

32

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100) : a prespecified analysis of a single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2022

von Fakih, M. | Kopetz, S. | Kuboki, Y. | +18

CommentIn: Lancet Oncol. 2022 Jan;23(1):10-11. - PMID 34919826

33

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors

enthalten in: The oncologist | 2021

von Do, K. | Chow, L. | Reckamp, K. | +13

34

Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

enthalten in: Clinical lung cancer | 2021

von Kao, C. | Powers, E. | Wu, Y. | +6

35

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Camidge, D. | Morgensztern, D. | Heist, R. | +14

36

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

enthalten in: Molecular cancer therapeutics | 2021

von Klempner, S. | Bendell, J. | Villaflor, V. | +8

37

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

enthalten in: Molecular cancer therapeutics | 2021

von Gordon, M. | Nemunaitis, J. | Barve, M. | +12

38

Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer

enthalten in: The oncologist | 2021

von Strickler, J. | Rushing, C. | Uronis, H. | +17

39

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy

enthalten in: Cell reports | 2021

von DeVito, N. | Sturdivant, M. | Thievanthiran, B. | +8

40

Tumor Mutational Burden as a Predictor of Immunotherapy Response : Is More Always Better?

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Strickler, J. | Hanks, B. | Khasraw, M.